Michael Rosenblatt

Exec V-P & Chief Med Officer, Merck & Co.

Companies

Azenta Life SciencesBoard member Sep 11, 2018 to Feb 13, 2024¹
Axcella Health (United States)Board member May 23, 2022 to May 23, 2022²
Rubius Therapeutics (United States)Board member Jul 17, 2018 to May 13, 2022³
Merck & Co.Exec V-P & Chief Med Officer Dec 16, 2009 to May 12, 2016⁴

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Azenta Life Sciences AZTA13,042 shares⁵$460.5K at $35.31Feb 12, 2024
Axcella Health (United States)3,053 shares⁶May 23, 2022

As of each latest filing. The line shows shares held over time.

Recent filings

Feb 12, 2024Granted 2,465 shares at $65.93 of Azenta Life Sciences⁵
Feb 13, 2023Granted 3,604 shares of Azenta Life Sciences⁷
Feb 11, 2022Granted 1,922 shares of Azenta Life Sciences⁸
Nov 12, 2021Sold 2,831 shares at $114.13 of Azenta Life Sciences⁹

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARAzenta Life Sciences, Board member
2
SEC EDGARAxcella Health (United States), Board member
3
SEC EDGARRubius Therapeutics (United States), Board member
4
SEC EDGARMerck & Co., Exec V-P & Chief Med Officer
5
SEC EDGARAzenta Life Sciences shares after the filing of Feb 12, 2024
6
SEC EDGARAxcella Health (United States) shares after the filing of May 23, 2022
7
SEC EDGARForm 4 filed Feb 15, 2023
8
SEC EDGARForm 4 filed Jun 9, 2022
9
SEC EDGARForm 4 filed Nov 15, 2021